Zantac Trial Dates Update

Zantac, the once ubiquitous heartburn drug, has come under scrutiny after being linked to several forms of cancer. GlaxoSmithKline, Sanofi, Pfizer and Boehringer Ingelheim, the manufacturers of Zantac, is facing thousands of lawsuits that have been consolidated in various jurisdictions due to the sheer number of Zantac lawsuits and the similar fact patterns common to the cases.

Most Zantac lawsuits are consolidated in a federal multidistrict litigation (“MDL”) before U.S. District Court Judge for the Southern District of Florida, the Honorable Robin L. Rosenberg.

The federal Zantac MDL is captioned 20-MD-2924-Rosenberg - In Re: Zantac (Ranitidine) Products Liability Litigation.

Zantac cases have also been filed in the following alternate jurisdictions to the MDL:  California, Florida, Illinois (Cook County), Minnesota (Minneapolis), New Jersey, New York, Oregon (Portland), Pennsylvania (Philadelphia) and Washington (Seattle).

Based on the latest pretrial order in the California Zantac JCCP, the first Zantac trial is scheduled for October 10, 2022 before Judge Grillo for the Superior Court of Alameda.

The Zantac MDL will likely hold its first trial in 2023, according to Judge Rosenberg’s pretrial order #65. “The Court’s vision is that bellwether trials will be conducted within 9-12 months following Daubert rulings.” Based on the order, that would slate the first Zantac MDL trial for mid-2023.  The trials have been delayed due to the defendants' tardy response to discovery demands. 

The federal judge in Florida presiding over Zantac multidistrict litigation (MDL) has denied requests by former manufacturers of the discontinued heartburn drug to dismiss a class action over the drug’s marketing and the severe health problems it has allegedly caused in tens of thousands of plaintiffs. 

Judge Robin Rosenberg ruled on Oct. 8 that Zantac makers, GlaxoSmithKline, Sanofi, Pfizer and Boehringer Ingelheim, are to face lawsuits filed by individuals who were formerly prescribed Zantac and are seeking compensation for future medical monitoring of cancer and for their financial losses, FiercePharma reported.